Company

Science Corporation

Develops retinal prosthesis implants to restore vision in patients with age-related macular degeneration.

Healthcare & Biotech

People

Funding History

Mar 6, 2026Series C

Science Corporation raised $230M in a Series C round, bringing total capital raised to just under $500M. Funds will support commercialization of its retinal prosthesis device in Europe following a successful clinical trial in age-related macular degeneration, and development of next-generation implants with more electrodes.

230M

News

Interviews (3)

Science Corporation receives CE Mark in Europe for retinal prosthesis that restores vision to the blind

22 Jul 2026

Science Corporation raises $230M after retinal implant helps blind patient finish a 300-page novel

6 Mar 2026

Science Corp's Max Hodak on restoring vision with a retinal chip — and the biohybrid brain interface beyond it

13 Nov 2025